Tyrosine Kinases are enzymes responsible for the activation of proteins by signal transduction cascades. Depending on the type of tyrosine kinase receptor, the mechanism of action of TKIs (Tyrosine Kinase Inhibitors) varies. Some of the TKIs bind to the extracellular domain of the RTKs (receptor tyrosine kinases) and prevent them from dimerizing and activating each other by cross-phosphorylation, thereby blocking the downstream signaling pathways that promote cell proliferation and survival. Other TKIs bind to the intracellular domain of the NRTKs (non-receptor tyrosine kinases) and compete with ATP to prevent the transfer of phosphate groups to the substrate proteins, thus inhibiting their activation. TKIs are primarily used for the treatment of lung cancer, breast cancer, renal cancer, and chronic myeloid leukemia. AstraZeneca, Novartis, Roche, Boehringer Ingelheim, and Bayer are the key companies that are currently providing tyrosine kinase inhibitors for the treatment of cancer patients in the market.
Key Developments
- In June 2023, Pfizer conducted trials using systematic inflammatory markers predicting the overall survival of patients using tyrosine kinase inhibitors in the first-line treatment of metastatic renal cell carcinoma.
- In June 2023, AstraZeneca’s Tagrisso’s (Osimertinib) future research potential on the development of EGFR-TKIs specific for exact allosteric sites to overcome acquired resistance and to reduce adverse events and the rising trend of EGFR inhibitors in the pharma market and their economic impact on real-world clinical practice were discussed.
Approved Drugs - Tyrosine kinase inhibitors
- IRESSA (Gefitinib)
- Erbitux (Cetuximab)
- NEXAVAR (Sorafenib)
- SUTENT (Sunitinib)
- VECTIBIX (Panitumumab)
- SPRYCEL (Dasatinib)
- TYKERB (Lapatinib)
- TORISEL (Temsirolimus)
- VOTRIENT (Pazopanib)
- XALKORI (Crizotinib)
- INLYTA (Axitinib)
- BOSULIF (Bosutinib)
- IMBRUVICA (Ibrutinib)
- GIOTRIF (Afatinib)
- CYRAMZA (Ramucirumab)
- ZYKADIA (Ceritinib)
- PORTRAZZA (Necitumumab)
- ALECENSA (Alectinib)
- PALBACE (Palbociclib)
- COTELLIC (Cobimetinib)
- TAGRISSO (Osimertinib)
- KISQALI (Ribociclib)
- VERZENIO (Abemaciclib)
- VIZIMPRO (Dacomitinib)
- LORBRENA (Lorlatinib)
- VIJOICE (Alpelisib)
- ROZLYTREK (Entrectinib)
- RETEVMO (Selpercatinib)
- EXKIVITY (Mobocertinib)
- RYBREVANT (Amivantamab)
Pipeline Drugs - Tyrosine Kinase Inhibitors
- TG-1701 - Phase-I
- BLU-285 (Avapritinib) - Phase-II
- BEMPEG:NKTR-214 - Phase-I
- Lenvatinib - Phase-II
- SNKO1 - Phase-I/II
- JNJ-42756493 (Erdafitinib) - Phase-II
- AL3818 - Phase-III
- Q702 - Phase-I
- BGB-311 (Zanubrutinib) - Phase-II
- MK-3475 (Pembrolizumab) - Phase-III
- ABL001 (Asciminib) - Phase-III
- LP-300 - Phase-I
Clinical Activity and Development of Tyrosine kinase inhibitors
With more than 50 FDA-approved drugs on the market for tyrosine kinase inhibition and further ongoing research and clinical trials by leading pharmaceutical companies, the market will see growth in recent future.
- In June 2023, Roche reported that Alecensa (Alectinib) in a comparative finding provided insight into the differential and beneficial effects of ancillary targeting beyond JAK2 and may help guide the specific inhibitors in personalized therapy.
- In June 2023, A phase-II study of Sintilimab, Anlotinib, and Pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I/II extranodal nature-killer/T-cell lymphoma resulted in high efficacy and low-toxicity.
- In June 2023, AbbVie and J&Js’ collaborative product Imbruvica’s (Ibrutinib) therapeutic actions as a BTK inhibitor were extremely helpful for patients with CLL, large B-cell lymphomas, and other non-Hodgkin’s lymphomas.
Target Indication Analysis of Tyrosine Kinase Inhibitors
The tyrosine kinase inhibitors market mainly consists of BCR-ABL TKIs, EGFR TKIs, VEGFR TKIs, BRAF kinase inhibitors, and ROS1 inhibitors. The molecules of tyrosine kinase inhibitors treat several kinds of cancer including HER2-positive breast cancer, brain-metastatic breast cancer, gastrointestinal stromal tumors, Waldenstrom macroglobulinemia, kidney cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, and non-small cell lungcancer. According to an article published in 2022, Imatinib, a tyrosine kinase inhibitor was successful in inhibiting cellular tyrosine kinase as well as viral fusion, thereby blocking the COVID-19 virus replication.
Regional Analysis of Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitors Market
J&J Services’s TKI, Imbruvica has seen a decline in its sales in the year 2022 to US$ 3,784 from US$ 4,369 due to competitive pressures and market suppression. Retevmo by J&J is protected by a compound patent (2037), and by data protection (2031) in the USA and European countries, and by a compound patent (2038) and by data protection (2029) in Japan. Breast cancer is the most common cancer occurring in women (22,61,419 patients globally) having the highest number of cancer rates in the USA (253,465 patients), followed by France (58,083), and Australia (19,617 patients). Similarly, some of the other indications of TKI such as kidney cancer have the maximum cancer rates in the USA (69,569 patients), followed by France (14,705) demonstrating them as the market with major growth potential for TKI.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Rybrevant (Amivantamab), Imbruvica (Ibrutinib), Retevmo (Selpercatinib), Exkivity (Mobocertinib), Vijoice (Alpelisib) and Verzenio (Abemaciclib) are some of the approved Tyrosine kinase inhibitors.
The global sale of Imbruvica for 2022 was US$ 5,784 million.
AstraZeneca, Novartis, Roche, Boehringer Ingelheim, and Bayer are a few major players in the Tyrosine kinase inhibitors space.
More than 23,00,000 women are affected by breast cancer globally.
HER2-positive breast cancer, brain-metastatic breast cancer, gastrointestinal stromal tumors, Waldenstsrom macroglobulinemia, kidney cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, and non-small cell lung cancer are some of the indications on which companies could focus on for the expansion of Tyrosine kinase inhibitors market.
- AbbVie (USA)
- Amgen (USA)
- Pfizer (USA)
- AstraZeneca (UK)
- Bayer (USA)
- Boehringer Ingelheim (Germany)
- Eli Lily (USA)
- Eisai Co. Ltd. (Japan)
- GSK (UK)
- Bristol Myers Squibb (USA)
- Exelixis Inc. (USA)
- J&J (USA)
- Incyte Corporation (USA)
- Novartis (Switzerland)
- Jiangsu Hansoh Pharma (China)
- Takeda Pharmaceuticals (USA)